Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA

Abstract

Introduction There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution.

Methods Information on the distribution of methylphenidate, amphetamine, and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement Administration’s comprehensive database and the three-year population-corrected slopes of stimulant distribution before and after MC program implementation were compared.

Results We found a significant main effect of time (p<0.001); however, contrary to the hypothesis, the sales status of states’ MC, did not influence slopes of distribution (p=0.391). There was a significantly large interaction effect of time and MC sales status on slopes of distribution (p<0.001). Slopes of distribution rates of stimulants were significantly lower in states that proceeded to legalize MC prior to MC program implementation than those states that did not (p=0.022). After MC program implementation, however, the distribution rates of the Schedule II stimulants were not significantly different when comparing states with MC sales to those without (p=0.355).

Discussion These findings suggest that MC program legalization did not contribute to certain states having rapid increases in Schedule II stimulant distribution rates over time. Other factors, including the liberalization of the adult ADHD diagnostic criteria in the DSM-5 and the introduction of Binge Eating Disorder, also likely contributed to elevations in stimulant distribution.

Key words

cannabis - marijuana - stimulants - attention-deficit/hyperactivity disorder (ADHD)

^* Authors contributed equally to the work: Garrett D. Alexander, Luke R. Cavanah

Publication History

Received: 09 February 2023
Received: 30 July 2023

Accepted: 03 August 2023

Article published online:
26 October 2023

• References

• 1 Piper BJ, Ogden CL, Simoyan OM. et al. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS One 2018; 13: e0206100 DOI: 10.1371/journal.pone.0206100.
• 2 Drug Enforcement Administration. Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling Stand: 19.04.2023
• 3 Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128: 1007-1022 DOI: 10.1542/peds.2011-2654.
• 4 International Narcotics Control Board, United Nations, International Narcotics Control Board. Availability of internationally controlled drugs: Ensuring adequate access for medical and scientific purposes: Indispensable, adequately available and not unduly restricted.. 2016
• 5 Board AR, Guy G, Jones CM. et al. Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty – United States, 2014–2019. Drug Alcohol Depend 2020; 217: 108297 DOI: 10.1016/j.drugalcdep.2020.108297.
• 6 Artigas MS, Sánchez-Mora C, Rovira P. et al. Attention-deficit/hyperactivity disorder and lifetime cannabis use: Genetic overlap and causality. Mol Psychiatry 2020; 25: 2493-2503 DOI: 10.1038/s41380-018-0339-3.
• 7 Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des 2014; 20: 2186-2193
• 8 Dennis M, Godley SH, Diamond G. et al. The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials. J Subst Abuse Treat 2004; 27: 197-213 DOI: 10.1016/j.jsat.2003.09.005.
• 9 Cawkwell PB, Hong DS, Leikauf JE. Neurodevelopmental effects of cannabis use in adolescents and emerging adults with ADHD: A systematic review. Harv Rev Psychiatry 2021; 29: 251-261 DOI: 10.1097/HRP.0000000000000303.
• 10 Haffajee RL, Heins S. State and community efforts to address stimulant use. US Dep Health Hum Serv. 2021
• 11 State Medical Cannabis Laws. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx; Stand: 24.07.2022
• 12 Drug Enforcement Administration, Diversion Control Division. ARCOS retail drug summary reports. U.S. Department of Justice. 2021
• 13 Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician 2014; 17: E119-E128
• 14 Bokhari F, Mayes R, Scheffler RM. An analysis of the significant variation in psychostimulant use across the U.S. Pharmacoepidemiol Drug Saf 2005; 14: 267-275 DOI: 10.1002/pds.980.
• 15 Collins LK, Pande LJ, Chung DY. et al. Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017. Prev Med 2019; 123: 95-100 DOI: 10.1016/j.ypmed.2019.02.017.
• 16 Davis CS, Piper BJ, Gertner AK. et al. Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution. Pain Med 2020; 21: 532-537 DOI: 10.1093/pm/pnz159.
• 17 Pashmineh Azar AR, Cruz-Mullane A, Podd JC. et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol Drug Saf 2020; 29: 708-715 DOI: 10.1002/pds.4984.
• 18 Piper BJ, McCall KL, Kogan LR. et al. Assessment of controlled substance distribution to U.S. veterinary teaching institutions from 2006 to 2019. Front Vet Sci 2020; 7: 615646 DOI: 10.3389/fvets.2020.615646.
• 19 Simpson KJ, Moran MT, Foster ML. et al. Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. BMJ Open 2019; 9: e027117 DOI: 10.1136/bmjopen-2018-027117.
• 20 Vaddadi SM, Czelatka NJ, Gutierrez BD. et al. Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States. PeerJ 2021; 9: e12619 DOI: 10.7717/peerj.12619.
• 21 Piper BJ, Shah DT, Simoyan OM. et al. Trends in medical use of opioids in the U.S., 2006–2016. Am J Prev Med 2018; 54: 652-660 DOI: 10.1016/j.amepre.2018.01.034.
• 22 Kaufman DE, Nihal AM, Leppo JD. et al. Opioid mortality following implementation of medical cannabis programs in the United States. Pharmacopsychiatry 2021; 54: 91-95 DOI: 10.1055/a-1353-6509.
• 23 Cohen. Statistical power analysis for the behavioral sciences. New York: Routeledge Academic; 1988
• 24 Babicki S, Arndt D, Marcu A. et al. Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Res 2016; 44: W147-W153 DOI: 10.1093/nar/gkw419.
• 25 Epstein JN, Loren REA. Changes in the definition of ADHD in DSM-5: Subtle but important. Neuropsychiatry 2013; 3: 455-458 DOI: 10.2217/npy.13.59.
• 26 Fulton BD, Scheffler RM, Hinshaw SP. State variation in increased ADHD prevalence: Links to NCLB school accountability and state medication laws. Psychiatr Serv 2015; 66: 1074-1082 DOI: 10.1176/appi.ps.201400145.
• 27 Guerdjikova AI, Mori N, Casuto LS. et al. Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine. Neuropsychiatr Dis Treat 2016; 12: 833-841 DOI: 10.2147/NDT.S80881.
• 28 Marco EM, Romero-Zerbo SY, Viveros M-P. et al. The role of the endocannabinoid system in eating disorders: Pharmacological implications. Behav Pharmacol 2012; 23: 526-536 DOI: 10.1097/FBP.0b013e328356c3c9.
• 29 Elbe D, MacBride A, Reddy D. Focus on Lisdexamfetamine: A review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2010; 19: 303-314
• 30 Scheffler RM, Hinshaw SP, Modrek S. et al. The global market for ADHD medications. Health Aff 2007; 26: 450-457 DOI: 10.1377/hlthaff.26.2.450.
• 31 Stueber A, Cuttler C. Self-reported effects of cannabis on ADHD symptoms, ADHD medication side effects, and ADHD-related executive dysfunction. J Atten Disord 2022; 26: 942-955 DOI: 10.1177/10870547211050949.